Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 11/20 | 0.58 |
| ▸ | F2 | P00734 | 1/20 | 0.46 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.46 |
| ▸ | CTRC | Q99895 | 3/20 | 0.44 |
| ▸ | CASP3 | P42574 | 1/20 | 0.42 |
| ▸ | CALCRL | Q16602 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | CASP1 | P29466 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.41 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.40 |
| ▸ | F10 | P00742 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8536815 | 0.86 | ELANE (0.67) | ELANECTRCCASP3NPC1RAB9A | |
| SCHEMBL7445689 | 0.84 | ELANE (0.60) | ELANECTRCCASP3NPC1RAB9A | |
| SCHEMBL8531683 | 0.83 | ELANE (0.59) | ELANECTRCCASP3NPC1RAB9A | |
| SCHEMBL7402310 | 0.82 | ELANE (0.60) | ELANECTRCCASP3NPC1RAB9A | |
| SCHEMBL1329615 | 0.80 | ELANE (0.65) | ELANEF2PRSS1CTRC | |
| SCHEMBL7276654 | 0.74 | ELANE (1.00) | ELANECTRC | |
| SCHEMBL7276644 | 0.73 | ELANE (0.76) | ELANECTRC | |
| SCHEMBL7441333 | 0.73 | ELANE (0.71) | ELANECTRC | |
| SCHEMBL21685578 | 0.72 | NPC1 (0.50) | ELANEF2PRSS1CTRCCASP3 | |
| SCHEMBL7276488 | 0.71 | ELANE (0.64) | ELANECTRCNPC1RAB9ACASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7994325-B2 | ligands for Calcitonin gene related peptide; azepinone ligands; migranes; N-[5-(2,3-Difluorophenyl)-1-(2-methoxyethyl)-2-oxopiperidin-3-yl]-4-(2-oxo-2,3-dihydro-1H-imidazo[4,5-b]pyridin-1-yl)piperidine-1-carboxamide | MERCK SHARP & DOHME CORP. (US) | 2011-08-09 | — | — | US | disclosed |
| US-20080261972-A1 | Cgrp Receptor Antagonists | MERCK SHARP & DOHME LLC | 2008-10-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080261972-A1 | Cgrp Receptor Antagonists | BDKRB1, CALCRL, NPY1R | ELANE 1124/4885F2 804/4885PRSS1 1377/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.